Article
A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy.
Haematologica - 1 Jul 2015
Borthakur Gautam, Dombret Herve, Schafhausen Philippe, Brummendorf Tim Henrik, Boissel Nicolas, Jabbour Elias, Mariani Mariangela, Capolongo Laura, Carpinelli Patrizia, Davite Cristina, Kantarjian Hagop, Cortes Jorge E
Abstract excerpt
Danusertib is a pan-aurora kinase inhibitor with potent activity against Abl kinase including the gatekeeper T315I mutant. A phase 1 dose escalation study of danusertib was conducted in patients with accelerated or blastic phase chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. Two dosing schedules were studied: schedule A, in which danusertib was given by 3-hour...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.